In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.7% at $51.31. This move outpaced the S&P 500's daily gain of 0.54%. Elsewhere, the Dow saw an upswing of 1.05%, while the tech-heavy Nasdaq appreciated by 0.56%.
The stock of company has fallen by 7.09% in the past month, lagging the Medical sector's loss of 1.89% and the S&P 500's gain of 0.74%.
The investment community will be paying close attention to the earnings performance of CRISPR Therapeutics AG in its upcoming release. The company's upcoming EPS is projected at -$1.15, signifying a 161.36% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $4 million, reflecting a 88.78% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$6.33 per share and a revenue of $8.54 million, demonstrating changes of -45.85% and 0%, respectively, from the preceding year.
Any recent changes to analyst estimates for CRISPR Therapeutics AG should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.43% lower. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 94, which puts it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
